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Introduction and Aim The only treatment of Laron Syndrome (LS), caused by an 
inherited defect in the gene encoding the GH receptor resulting in the failure to generate 
IGF-1, consists of chronic administration of recombinant human IGF−1 (rhIGF-1) that is 
burdened side effects. Moreover, this approach is limited by the restricted availability of 
this drug for clinical use (orphan drug) which dramatically lowers number of treatable 
cases. It is known that IGF-1 represents one of the main growth factors produced by 
Sertoli cells (SC). Aim of our work was to assess if transplantation of barium alginate mi-
croencapsulated SC (BaMCs) would induce normalization of clinical features of growth 
hormone deficiency in “Laron mice”, the best animal model for human LS.
Materials and Methods BaMCs were prepared from pre-pubertal piglets, according 
to our method and examined as far as: (a) SC morphology by light microscopy; (b) SC 
viability, by fluorescence microscopy after staining with ethidium bromide and fluores-
cein diacetate (EB+FDA); (c) SC in vitro function (α-aromatase activity and IGF-I secre-
tion); (d) evaluation of growth parameters in Laron transplanted mice were concerned.
Results BaMCs showed excellent features in terms of size, morphology, sphericity 
and coalescence. SC viability was very high (over 90%). Very good α-aromatase activity 
and IGF-I secretion were associated with the examined SC preparation. Intraperitoneal 
graft of BaMCs into Laron mice induced a significant increase in growth parameters in 
terms of weigth and nose-to-anus length as compared to untreated controls.
Conclusions SC may be enveloped in BaMCs with no loss of their functional and 
morphological properties. Xenograft of BaMCs in Laron mice induced, an unprecedent-
ed, significant increase in growth parameters as compared to untreated controls. This 
result may open new perspectives for therapy of human LS. 
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